RT Journal Article
SR Electronic
T1 Seroprevalence of Antibodies to SARS-CoV-2 among Health Care Workers in Kenya
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.12.21253493
DO 10.1101/2021.03.12.21253493
A1 Etyang, Anthony O.
A1 Lucinde, Ruth
A1 Karanja, Henry
A1 Kalu, Catherine
A1 Mugo, Daisy
A1 Nyagwange, James
A1 Gitonga, John
A1 Tuju, James
A1 Wanjiku, Perpetual
A1 Karani, Angela
A1 Mutua, Shadrack
A1 Maroko, Hosea
A1 Nzomo, Eddy
A1 Maitha, Eric
A1 Kamuri, Evanson
A1 Kaugiria, Thuranira
A1 Weru, Justus
A1 Ochola, Lucy B.
A1 Kilimo, Nelson
A1 Charo, Sande
A1 Emukule, Namdala
A1 Moracha, Wycliffe
A1 Mukabi, David
A1 Okuku, Rosemary
A1 Ogutu, Monicah
A1 Angujo, Barrack
A1 Otiende, Mark
A1 Bottomley, Christian
A1 Otieno, Edward
A1 Ndwiga, Leonard
A1 Nyaguara, Amek
A1 Voller, Shirine
A1 Agoti, Charles
A1 Nokes, David James
A1 Ochola-Oyier, Lynette Isabella
A1 Aman, Rashid
A1 Amoth, Patrick
A1 Mwangangi, Mercy
A1 Kasera, Kadondi
A1 Ng’ang’a, Wangari
A1 Adetifa, Ifedayo
A1 Kagucia, E. Wangeci
A1 Gallagher, Katherine
A1 Uyoga, Sophie
A1 Tsofa, Benjamin
A1 Barasa, Edwine
A1 Bejon, Philip
A1 Scott, J. Anthony G.
A1 Agweyu, Ambrose
A1 Warimwe, George
YR 2021
UL http://medrxiv.org/content/early/2021/03/13/2021.03.12.21253493.abstract
AB Background Few studies have assessed the seroprevalence of antibodies against SARS-CoV-2 among Health Care Workers (HCWs) in Africa. We report findings from a survey among HCWs in three counties in Kenya.Methods We recruited 684 HCWs from Kilifi (rural), Busia (rural) and Nairobi (urban) counties. The serosurvey was conducted between 30th July 2020 and 4th December 2020. We tested for IgG antibodies to SARS-CoV-2 spike protein using ELISA. Assay sensitivity and specificity were 93% (95% CI 88-96%) and 99% (95% CI 98-99.5%), respectively. We adjusted prevalence estimates using Bayesian modeling to account for assay performance.Results Crude overall seroprevalence was 19.7% (135/684). After adjustment for assay performance seroprevalence was 20.8% (95% CI 17.5-24.4%). Seroprevalence varied significantly (p<0.001) by site: 43.8% (CI 35.8-52.2%) in Nairobi, 12.6% (CI 8.8-17.1%) in Busia and 11.5% (CI 7.2-17.6%) in Kilifi. In a multivariable model controlling for age, sex and site, professional cadre was not associated with differences in seroprevalence.Conclusion These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the Wellcome Trust (grants 220991/Z/20/Z and 203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-017547), and the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated programme of SARS-CoV-2 serosurveillance in Kenya led by KEMRI Wellcome Trust Research ProgrammeAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI/SERU/CGMR-C/203/4085)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data are avaialble upon reasonable request